Compare Eli Lilly And Co (LLY) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Thomson Reuters Corp — how do they compare? Eli Lilly And Co trades at $1,173.56 (market cap $1.04T), while Thomson Reuters Corp trades at $103.31 (market cap $43.89B). The key difference: Eli Lilly And Co is far larger — about 23.7× Thomson Reuters Corp's market cap, and Thomson Reuters Corp pays the higher dividend (2.58%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Thomson Reuters Corp for 63 Days on average.
| LLY | TRI | |
|---|---|---|
Market Cap | $1.04T | $43.89B |
Volume | 3,064,878 | 1,648,199 |
Sector | Health | Industrials |
52-Week High | $1.28K | $163.45 |
52-Week Low | $799.57 | $76.55 |
Typical Hold Time | 93 Days | 63 Days |
Enterprise Value | $1.09T | $46.51B |
Dividend Yield | 0.59% | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Thomson Reuters (TRI) trades at $101.71, up 2.45% today, with a bullish technical outlook and strong analyst consensus. The stock shows robust fundamentals with a 21.22% net income margin and 10% organic growth in core businesses. Recent strategic moves include divesting its print unit to focus on technology and launching a proprietary AI model, positioning for future growth.
The outlook is positive with a consensus price target of $133.25, implying significant upside. Key risks include execution of the AI strategy and cybersecurity concerns. Institutional buying and insider purchases support confidence, but investors should monitor earnings performance and competitive pressures in the legal tech space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
